Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
| ▸ | GRK6 | P43250 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701285 | 0.91 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247008 | 0.89 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL10000103 | 0.85 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247003 | 0.85 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247043 | 0.85 | CFTR (0.43) | SLC6A2CFTRSLC6A4SLC6A3GOPC | |
| SCHEMBL13267920 | 0.84 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL3017476 | 0.83 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247013 | 0.83 | BRAF (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247002 | 0.82 | ADRA2A (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13247040 | 0.81 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162450-B1 | ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS | ALLERGAN INC (US) | 2015-02-25 | — | — | EP | disclosed |
| CN-101711242-B | ((bicyclic heteroaryl) imidazolyl) methyl heteroaryl compounds as adrenergic receptor agonists | ALLERGAN INC | 2013-09-25 | — | — | CN | disclosed |
| US-8383646-B2 | Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383646-B2 | Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383646-B2 | Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100190823-A1 | Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds | ALLEGERGAN INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190823-A1 | Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds | ALLEGERGAN INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190823-A1 | Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds | ALLEGERGAN INC. (US) | 2010-07-29 | — | — | US | disclosed |
| CN-101711242-A | ((bicyclic heteroaryl) imidazolyl) methyl heteroaryl compounds as adrenergic receptor agonists | ALLERGAN INC | 2010-05-19 | — | — | CN | disclosed |
| EP-2162450-A1 | ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008147786-A1 | ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008147786-A1 | ((BICYLICHETEROARYL) IMIDAZOLYL) METHYLHETEROARYL COMPOUNDS AS ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190823-A1 | Therapeutic ((Bicylicheteroaryl)Imidazolyl) Methylheteroaryl Compounds | OAT, HMGCR, GOT2 | ADRA2A 1446/4885ADRA2B 1766/4885ADRA2C 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.